TNF -308G > A promoter polymorphism (rs1800629) and outcome from critical illness

Brazilian Journal of Infectious Diseases

Volumn 15, Issue 3, 2011, Pages 231-238

  Paskulin, Diego D'Ávila ^a   Fallavena, Paulo R V ^b   Paludo, Francis J O ^b   Borges, Tiago J ^a   Picanço, Juliane B ^b   Dias, Fernando S ^a   Alho, Clarice Sampaio ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Associated peptides and proteins; Critical care; Polymorphism, single nucleotide; Tumor necrosis factor receptor

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ALLELE; ARTICLE; BRAZIL; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; CRITICAL ILLNESS; DISEASE ASSOCIATION; DISEASE COURSE; DNA POLYMORPHISM; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENOTYPE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; OBSERVATIONAL STUDY; PATIENT MONITORING; PREDICTIVE VALUE; PROMOTER REGION; SCORING SYSTEM; SEPSIS; SEPTIC SHOCK;

EID: 79959624842     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/S1413-8670(11)70181-7     Document Type: Article

References (49)

1. Resche-Rigon M, Azoulay E, Chevret S. Evaluating mortality in intensive care units: contribution of competing risks analyses. Crit Care 2006; 10:103.
2. Poikonen K, Lajunen T, Silvennoinen-Kassinen S et al. Efects of CD14, TLR2, TLR4, LPB, and IL-6 Gene Polymorphisms on Chlamydia pneumoniae Growth in Human Macrophages In Vitro. Scand J Immunol. 2009; 7:30-9.
3. Medzhitov R, Janeway CA Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell 1997; 91:295-8.
4. Arancibia SA, Beltran CJ, Aguirre IM Silva P et al. Toll-like receptors are key participants in innate immune responses. Biol Res 2007/40:97-112.
5. Dobrovolskaia MA, Vogel SN: Toll receptors, CD14, and macrophage activation and deactivation by LPS. Microbes Infect 2002; 4:903-14.
6. O'Shea JJ, Ma A, Lipsky P. Cytokines and Autoimmunity. Nat Rev Immunol. 2002; 2:37-45.
7. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104:487-501.
8. Schottelius AJ, Moldawer LL, Dinarello CA et al. Biology of tumor necrosis factor-alpha - implications for psoriasis. Exp Dermatol. 2004; 13:193-222.
9. Wood LJ, Nail LM, Gilster A, Winters KA. Cancer chemotherapy-related symptoms: Evidence to suggest a role for proin-flammatory cytokines. Oncol Nurs Forum 2006; 33(3):535-42.
10. Wilson AG, di Giovine FS, Blakemore AI, Duf GW. Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. Hum Mol Genet. 1992; 1(5):353.
11. Wunderink RG, Waterer GW. Genetics of sepsis and pneumonia. Curr Opin Crit Care 2003; 9(5):384-9.
12. Grohe SS, Stuber F, Book M. TNF-a Promoter Polymorphism in Relation to TNF-a Production and Clinical Status in Cystic Fibrosis. Lung 2006; 184:99-104.
13. Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-α promoter polymorphism efects transcription. Mol Immunol. 1997; 34(5):391-9.
14. Wilson AG, Symons JA, McDowell TL et al. Efects of a polymorphism in the human tumor necrosis factor-α promoter on transcriptional activation. Immunol. 1997; 94:3195-9.
15. Beutler B. Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234(4775):470-4.
16. Stüber F, Petersen M, Bokelmann F, Schade U. A genomic polymorphism within the tumor necrosis factor locus infuences plasma tumor necrosis factor-a concentrations and outcome of patients with severe sepsis. Crit Care Med. 1996; 24(3):381-4.
17. Mira J P, Cariou A, Grall F et al. Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. JAMA 1999; 282(6):561-8.
18. Tang GJ, Huang SL, Yien HW et al. Tumor necrosis factor gene polymorphism and septic shock in surgical infection. Crit Care Med. 2000; 28(8):2733-6.
19. Appoloni O, Dup ont E, Vandercruys M et al. Association of Tumor Necrosis Factor-2 Allele with Plasma Tumor Necrosis Factor-alpha Levels and Mortality from Septic Shock. Am J Med. 2001; 110(6):486-8.
20. Waterer GW, Quasney MW, Cantor RM, Wunderink RG. Septic shock and respiratory failure in community-acquired pneumonia have diferent TNF polymorphism associations. Am J Resp Crit Care Med. 2001; 163(7):1599-604.
21. O'Keefe GE, Hybki DL, Munford RS. The G-A single nucleotide polymorphism at the -308 position in the tumor necrosis factor-alpha promoter increases the risk for severe sepsis afer trauma. J Trauma 2002; 52(5):817-25.
22. Reid CL, Perrey C, Pravica V et al. Genetic variation in proinfam-matory and anti-infammatory cytokine production in multiple organ dysfunction syndrome. Crit Care Med. 2002; 30(10):2216-21.
23. Gordon AC, Lagan AL, Aganna E et al. TNF and TNFR polymorphisms in severe sepsis and septic shock: a prospective multicentre study. Genes Immun. 2004; 5(8):631-40.
24. Jessen KM, Lindboe SB, Petersen AL et al. Common TNF-α, IL-1 , PAI-1, uPA, CD14 and TLR4 polymorphisms are not associated with disease severity or outcome from Gram negative sepsis. BMC Infect Dis. 2007; 18;7:108.
25. American College of Chest Physicians/Society of Critical Care Medicine. Consensus Conference: de nitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992; 20(6):864-74.
26. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classi cation system. Crit Care Med. 1985; 13(10):818-29.
27. Vincent JL, Moreno R, Takala J et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Int Care Med. 1996; 22(7):707-10.
28. Lahiri DK, Nurnberger Jr JI. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucl Acids Res. 1991; 19(19):5444.
29. Kauss IA, Grion CM, Cardoso LT et al. The epidemiology of sepsis in a Brazilian teaching hospital. Braz J Infect Dis. 2010; 14(3):264-70
30. Garnacho-Montero J, Aldabo-Pallas T, Garnacho-Montero C et al. Timing of adequate antibiotic therapy is a greater determinant of outcome than are TNF and IL-10 polymorphisms in patients with sepsis. Crit Care 2006; 10(4):R111.
31. Clark MF, Baudouin S V. A systematic review of the quality of genetic association studies in human sepsis. Int Care Med. 2006; 32(11):1706-12.
32. Newton-Cheh C, Hirschhorn JN. Genetic association studies of complex traits design and analysis issues. Mutation Research 2005; 573(1-2):54-69.
33. Lohmueller KE, Pearce CL, Pike M et al. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet. 2003; 33:177-82.
34. Cardon LR, Bell JI. Association study designs for complex diseases. Nat Rev Genet. 2001; 2(2):91-9.
35. Ioannidis JPA, Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis DG. Genetic associations in large versus small studies: an empirical assessment. Lancet 2003; 361(9357):567-71.
36. Todd JA. Statistical false positive or true disease pathway? Nat Genet. 2006; 38(7):731-3.
37. Bogardus ST Jr, Concato J, Feinstein AR. Clinical epidemiological quality in molecular genetic research: The need for methodological standards. JAMA 1999; 281(20):1919-26.
38. NCI-NHGRI Working Group on Replication in Association Studies. Replicating genotype-phenotype associations. Nature 2007; 447(7145):655-60.
39. Louis E, Franchimont D, Piron A et al. Tumour necrosis factor (TNF) gene polymorphism infuences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol. 1998; 113(3):401-6.
40. Cohen J, Carlet J. INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis: International Sepsis Trial Study Group. Crit Care Med. 1996; 24:1431-40.
41. Abraham E, Anzueto A, Guttierez G et al. Double-blind randomized controlled trial of monoclonal antibody to human tumour necrosis factor in the treatment of septic shock. The NORASEPT II Study Group. Lancet 1998; 351(9107):929-33.
42. Colhoun HM, McKeigue PM, Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet 2003; 2003 8:361(9360): 865-872.
43. Peters DL, Barber RC, Flood EM et al. Methodologic quality and genotyping reproducibility in studies of tumor necrosis factor -308 G-A single nucleotide polymorphism and bacterial sepsis: implications for studies of complex traits. Crit Care Med. 2003; 31(6):1691-6.
44. Vitali SH, Randolph AG. Assessing the quality of case-control association studies on the genetic basis of sepsis. Pediatr Crit Care Med. 2005; 6:S74-7.
45. Trikalinos TA, Salanti G, Khoury MJ, Ioannidis J P. Impact of violations and deviations in Hardy-Weinberg equilibrium on postulated gene-disease associations. Am J Epidemiol. 2006; 15(4):300-9.
46. Salzano FM, Freire-Maia N. Problems in human biology. A study of Brazilian populations. Detroit, Wayne State University Press, 1970.
47. Parra FC, Amado RC, Lambertucci JR e t al. Color and genomic ancestry in Brazilians. Proc Natl Acad Sci USA 2003; 100(1):177-82.
48. Watanabe Y, Muratake T, Kaneko N, Fukui N, Nara Y, Someya T. No ssociation between the tumor necrosis factor-alpha gene promoter polymorphisms and schizophrenia in a Japanese population.Psychiatry Res. 2007 Sep 30;153(1):1-6. Epub 2007 Jun 7.
49. Hajeer AH, Hutchinson IV. Infuence of TNFalpha gene polymorphisms on TNFalpha production and disease. Hum Immunol. 2001 Nov;62(11):1191-9.